|
|
|
資訊服務
巴西・俄羅斯・印度・中國藥品市場
The Market for Pharmaceuticals in Brazil, Russia, India & China
|
巴西・俄羅斯・印度・中國藥品市場 是由出版商Espicom Business Intelligence在Issues / Year: 4所出版的。
這份英文資訊服務價格從美金3490起跳。
本年度訊息服務內容包括：BRIC各國（巴西、俄羅斯、印度、中國）政治・經濟・人口動向、醫療制度、醫療費用支出、醫療設施、規範環境、通路、國内生產動向等彙整市場背景的國別報告書及藥品市場結構、規模、每季提供的國別2014年之前的5年預測報告。內容綱要摘記如下：
提供内容
- 國別分析
- 國家相關指標
- 經濟相關資料預測
- 人口相關資料預測
- 醫療相關資料預測
- 醫療系統
- 組織・機構
- 醫療費用支出：財源・類型別
- 醫院服務資料
- 門診患者照護
- 醫療從業人員
- 接觸藥品市場
- 聯絡資訊
- 每季更新的報告書
- 市場規模
- 5年市場預測（至2014年）
- 市場預測・結構
- 評析・評鑑
- 進出口資料
- 市場發展動向
Abstract
These insightful reports provide:
- Five-year projections for economic, demographic, health expenditure,
health workforce and pharmaceutical market indicators.
- Specialised intelligence on OTCs, generics, biologics and biosimilars.
- Exclusive economic and demographic data from the Economist Intelligence
Unit (EIU) for each market in the series.
- A separate statistical health file, comprising health expenditure, health
infrastructure, health services and health personnel.
Putting things in perspective
The BRIC pharmaceutical markets, including pharmacy and hospital sales, are
currently valued at US$103.3 billion at retail prices. This is a large sum of
money, but is collectively lower than that found in leading markets such as
the USA and Japan. Growth rates vary but, overall, they are impressive.
Opportunities do exist
There are wide regional differences in expenditure levels within the BRIC
markets, far more so than in developed countries where health systems have
evolved to provide a more uniform level of coverage. All four countries have a
relatively wealthy urban population with a far greater spending power than
their respective national average. In the case of China and India, these urban
populations have grown rapidly, and number hundreds of millions. The challenge
for these countries is to extend this level of wealth to the rest of the
population, in order that better levels of healthcare become affordable.
A long haul
This is evolution not revolution, and change will be incremental. Short-term
opportunities exist in meeting the health demands of the burgeoning middle
classes, and future prospects are bright, where steady growth in BRIC markets
will erode commercial differences with the established markets in North
America, Japan and Europe.
HIGHLIGHTS FROM THE REPORTS...
BRAZIL
Brazil is the second most attractive BRIC market for pharmaceutical producers.
Controlled drug prices have increased below inflation levels but price
controls are not directly linked to consumption levels. In fact, between 1997
and 2008, the pharmaceutical market by volume increased significantly only in
2004. Demand should increase as the country is emerging from the economic
downturn much quicker than anticipated, therefore the outlook is positive
compared to other Latin American markets. The exchange rate of the real
against the US dollar fell in early 2009, but it has now recovered. This is
good news for producers as imports are now cheaper; Brazil, contrary to what
happens in other BRIC countries such as India, still relies on raw material
imports, which diminishes its market strength. Recent regulatory developments
include the implementation of the National Drug Control System, published in
November 2009; registration requirements for APIs, published in November 2009;
and a new labelling & packaging regulation, published in September 2009.
ANVISA is also working on a draft for the regulation of biologic copies; the
aim is to encourage local production of these medicines.
RUSSIA
The country has a sizeable generic industry, but the local production of
innovative drugs is negligible. Foreign companies such as Stada Arzneimittel
are starting to enter the market through the acquisition of domestic
companies. Around 75% of the market is supplied by imports. Germany and France
are the leading suppliers, accounting for over 30% of imports. Many importers
are CEE generic companies such as Gedeon Richter, KRKA and Lek. The market
environment remains challenging for overseas companies. Major problems
reported include corruption, bureaucracy, counterfeiting and poor data
confidentiality. Government officials and politicians often discriminate in
favour of the domestic industry, and enforcement of existing rules is often
weak. Funding reform is on the cards with the current system being replaced by
compulsory health insurance. Currently, free medicines are provided to people
receiving state benefits or who are hospitalised; the new system will provide
free or low-cost prescription drugs to all Russians. However, it has been
reported that only Russian produced drugs will be subsidised under the new
arrangements.
INDIA
The pharmaceutical market is highly competitive and remains dominated by low
priced, domestically-produced generics. The domestic industry is, however,
export-oriented and larger companies are competing in the global market for
both generics and original products. A number of companies are collaborating
with international pharmaceutical companies. In March 2010, it was announced
that AstraZeneca had signed a licence and supply agreement with Torrent for a
portfolio of generic medicines for which Torrent already has licences in a
range of countries. Working in partnership with Torrent, AstraZeneca intends
to brand and market these products in many of its emerging markets, where it
already has a strong commercial footprint. AstraZeneca will initially purchase
from Torrent the licences and market authorisations for 18 products in nine
countries and has the flexibility to add further products and new countries
where the company sees opportunities for growth. Pfizer has also announced
collaborative agreements with Indian companies, most recently with Strides
Arcolab in January 2010. The Strides deal will provide Pfizer with around 40
off-patent products, mainly cancer therapies, which the firm will
commercialise in the US.
CHINA
The increased presence of multinational firms in China, the requirements of
the WTO, and current excess capacity all mean that increasing pressure is on
the domestic industry to do more than just duplicate existing products. As a
result, pharmaceutical R&D is increasingly being encouraged by the Chinese
government. Around one third of China' s provinces have highlighted the
pharmaceutical industry as a target for development, and universities and
manufacturers often collaborate closely on research projects. The SFDA has
laid out a number of exemptions from import duties and other custom taxes that
foreign companies can benefit from if they undertake R&D in the country.
Foreign companies involved in joint-ventures are likely to benefit from the
exemptions to a much greater extent than those which are not. The SFDA' s
longer term objective is to produce proprietary medicines which are able to
compete on the international market.
Table of Contents
BRAZIL
- EXECUTIVE SUMMARY
- Introduction
- Pharmaceutical Market Analysis
- Pharmaceutical Regulatory Analysis
- Pharmaceutical Distribution Analysis
- Healthcare Analysis
- Economic Analysis
- Political Analysis
- Geographic Analysis
- Pharmaceutical Market Analysis
- Current Size
- Market Structure
- Pharmacy Sector
- Generic Sector
- OTC Sector
- Public Sector
- Projections & Outlook
- Imports
- Manufacturing
- Trade Associations
- ABIMIP
- ALANAC
- ALFOB
- FEBRAFARMA
- INTERFARMA
- Pro-Genericos
- Trade Fairs
- ABRADILAN FARMA & HPC
- ECONOFARMA
- EXPO FARMACIA
- EXPO PHARMA
- FCE PHARMA
- Hospitalar
- SHOPFARMA
- TOPFARMA
- Local Manufacturers
- Ache
- Americano
- Cimed
- CPPI
- Cristalia
- EMS
- Eurofarma
- FURP
- Hemobras
- Hipolabor
- LAFEPE
- Libbs Farmaceutica
- Mantecorp
- Neo Quimica
- Prati-Donaduzzi
- Uniao Quimica
- Multinational Manufacturers
- AstraZeneca
- Bayer
- Boehringer Ingelheim
- Daiichi-Sankyo
- GlaxoSmithKline
- Johnson & Johnson
- Merck
- Merck Sharp & Dohme
- Novartis
- Novo Nordisk
- Nycomed
- Pfizer
- Roche
- sanofi-aventis
- Servier
- Zambon
- Zydus Cadila
- Exports
- Research & Development
- Pharmaceutical Regulatory Analysis
- MERCOSUR Regulation
- National Regulation
- Registration
- Imports
- Clinical Trials
- Generics
- Labelling & Packaging
- Quality Control
- Traceability
- Advertising
- Pharmacies
- Regulation of Dispensing Practices
- Pricing & Reimbursement
- Pricing
- Reimbursement
- Farmacia Popular do Brasil
- Intellectual Property Rights
- Patent Rejection of Tenofovir
- Compulsory Licence for Efavirenz
- Pharmaceutical Distribution
- Wholesaling
- Distribution Trade Associations
- Distributors
- Athos Farma
- Panpharma
- Profarma
- Santa Cruz
- Retailing
- Pharmacy & Drugstore Chains
- Pharmacy Chain Associations
- ABRAFARMA
- ASSIFARMA
- FEBRAFAR
- Pharmacy Chains
- Drogamed
- Droga Raia
- Drogaria Araujo
- Drogaria Sao Paulo
- Drogarias Pacheco
- Drogasil
- Drogasmil
- Farmacias Pague Menos
- Panvel Farmacias
- Healthcare Analysis
- Demographics
- Population
- Birth Rate
- Death Rate
- Infant Mortality
- Life Expectancy at Birth
- Public Health
- Causes of Death
- Incidence of Communicable Diseases
- Incidence of Non-Communicable Diseases
- Vaccination
- Healthcare System
- Second Disease Surveillance & Control Project
- Bahia Health System Reform Project
- Health Insurance
- Health Expenditure
- Public Health Expenditure
- Federal Health Expenditure
- Healthcare Infrastructure
- Healthcare Establishments
- Healthcare Resources
- Healthcare Activity
- Inpatient Care Analysis
- Ambulatory Care Analysis
- Healthcare Personnel
- Directory
- Government Organisations
- Trade Associations
- Methodology & Sources
List of Tables
- Summary of Key Data Projections, 2009-2014
- Summary of the Brazilian Pharmaceutical Market, 2009
- Pharmaceutical Market, 1997-2009
- Pharmaceutical Market Value by Month, 2000-2009 (R$ Million)
- Pharmaceutical Market Value by Month, 2000-2009 (US$ Million)
- Pharmaceutical Market Volume by Month, 2000-2009 (Million Units)
- Pharmacy Sector by Value & Volume, 2001-2008
- Generic Pharmacy Sales by Value & Volume, 2000-2008
- Pharmaceutical Market Projections, 2009-2014
- SWOT Analysis of the Brazilian Pharmaceutical Market, 2009
- Espicom Analysis of the Brazilian Pharmaceutical Market, 2009
- Pharmaceutical Imports by Category, 2003-2007 (US$000s)
- Pharmaceutical Import Trends by Category, 2006-2007 (US$000s)
- Leading Suppliers of Raw Materials, 2007 (US$000s)
- Leading Suppliers of Antisera & Vaccines, 2007 (US$000s)
- Leading Suppliers of Medicaments, 2007 (US$000s)
- Pharmaceutical Manufacturing Units by Leading State, 2002-2007
- Pharmaceutical Workforce by Leading State, 2002-2007
- Pharmaceutical Gross Production by Leading State, 2002-2007 (R$ Million)
- Pharmaceutical Gross Production by Companies with 30+ Employees, 2007 (R$
000s)
- Pharmaceutical Gross Production by Manufacturing Units with 30+ Employees,
2007 (R$ 000s)
- Members of ABIMIP, 2008
- Members of ALANAC, 2008
- Members of ALFOB, 2008
- Members of FEBRAFARMA, 2008
- Members of INTERFARMA, 2008
- Members of Pro-Genericos, 2008
- Cimed' s Sales, 2004-2007
- LAFEPE' s Product Lines, 2007
- Libbs' Pharmaceutical Sales, 2000-2006
- AstraZeneca' s Sales by Sector, 2005-2007 (R$ Million)
- Boehringer Ingelheim' s Key Indicators, 2002-2008
- Novartis' Sales by Division, 2006-2007 (R$ Million)
- Roche' s Gross Sales, 2006-2008
- Medley' s Pharmacy Sales by Value, 2003-2007
- Medley' s Generic Sales by Volume, 2003-2007
- Leading Generic Producers by Market Share Value, 2005-2007
- Zambon' s Sales, 2005-2008
- Pharmaceutical Exports by Category, 2003-2007 (US$000s)
- Pharmaceutical Export Trends by Category, 2006-2007 (US$000s)
- Leading Destinations of Raw Materials, 2007 (US$000s)
- Leading Destinations of Medicaments, 2007 (US$000s)
- Pharmaceutical Investments by Type, 2007
- Members of ABAFARMA, 2008
- Members of ABRAFARMA, 2008
- Members of ASSIFARMA, 2008
- Members of FEBRAFAR by Region, 2008
- Drogasil' s Sales, 2004-2008 (R$ Million)
- Pague Menos' Sales, 2005-2008
- Projected Population, 2009-2014
- Summary of Projected Demographic Data, 2009
- Health Insurers, 2000-2008
- Beneficiaries with Medical Services (With/Without Odontology) by Contract
Type, 2000-2008
- Projected Health Expenditure, 2009-2014
- Healthcare Establishments by Provider & Type, January 2009
- Healthcare Establishments by Region & Type, January 2009
- Summary of Healthcare Establishments by Type of Service, January 2009
- Hospital Bed Projections, 2009-2014
- Hospitals & Beds, 2009
- Inpatient Beds by Provider & Establishment, February 2009
- Summary of Medical Equipment by Type, February 2009
- Summary of Existing Medical Equipment by Provider & Type, February 2009
- Summary of Existing Medical Equipment by Region & Type, February 2009
- SUS Hospital Admissions by Specialty, 2008
- SUS Hospital Admissions by Provider, 2000-2008
- SUS Hospital Admissions by Region, 2000-2008
- SUS Ambulatory Procedures by Type, 2008
- Approved SUS Ambulatory Procedures by Provider, 2000-2008
- Approved SUS Ambulatory Procedures by Region, 2000-2008
- Projected Number of Physicians, 2009-2014
List of Charts
- Pharmaceutical Market, 1997-2009
- Radar Graph of the Brazilian Pharmaceutical Market, 2009
- Pharmaceutical Imports, 1997-2007 (US$ Millions)
- Pharmaceutical Imports by Category, 2007 (%)
- Leading Suppliers of Pharmaceuticals, 2007 (%)
- Number of Pharmaceutical Producers, 1997-2007
- Pharmaceutical Workforce, 1997-2007
- Pharmaceutical Gross Production, 1997-2007
- Pharmaceutical Gross Production by Manufacturing Type, 2007 (%)
- Pharmaceutical Exports, 1997-2007 (US$000s)
- Pharmaceutical Exports by Category, 2007 (%)
- Leading Destinations of Pharmaceuticals, 2007 (%)
- Balance of Trade in Pharmaceuticals, 1997-2007 (US$ Million)
- Pharmacy Market Share by Retail Type, 2008 (%)
CHINA
- EXECUTIVE SUMMARY
- Introduction
- Pharmaceutical Market Analysis
- Size
- Market Structure
- Projections & Outlook
- Imports
- Domestic Manufacturing
- Domestic Production
- 11th Five Year Plan Targets
- Local Manufacturers
- Aida Pharmaceuticals
- Anhui Anke Biotech
- Beijing Four Ring Biopharmaceutical Co. Ltd.
- Changzhou Siyao Pharmaceuticals Co. Ltd
- China Pharmaceutical Enterprise
- China Sky One Medical
- Dragon Pharmaceuticals
- Fuzhou Antibiotic Group Corp
- Haizhou Pharmaceutical Co. Ltd
- Harbin Pharmaceutical Group Co. Ltd
- Heshuo Ephedrine Factory
- Huazhong Pharmaceutical Co. Ltd
- Jiangsu Jiangan Pharmaceutical Corp Ltd
- Jiuyuan
- Livzon (Group) Libao Biochemical & Pharmaceutical Co Ltd
- Ningbo Jierfu Pharmaceutical Co Ltd
- North China Pharmaceutical Huasheng Co. Ltd
- Shenyang Sunshine Pharmaceutical Co Ltd
- Shenzhen Kexing Biotech
- Shenzhen Zhijun Pharmaceutical Company
- Shenzhen Taitai Pharmaceutical Industry (Taitai)
- Sinovac Biotech Ltd.
- Wenzhou Pharmaceutical Factory
- Xiamen No.2 Pharmaceutical Factory
- Xinhua Pharma
- Yiyuan Pharmaceutical Co Ltd
- Zhejiang Jinhua Lixin Fine Chemicals Co Ltd
- Traditional Chinese Medicine
- Manufacturers
- China Conducts Research on Toxicity and Side Effects of TCM
- Multinational Manufacturers
- Allergan
- Antibioticos
- Astellas Pharma
- AstraZeneca
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Daiichi Sankyo
- Dainippon Sumitomo Pharma
- Eisai
- Eli Lilly
- GlaxoSmithKline
- Johnson & Johnson
- Laboratories Servier
- Merck KGaA
- Merck Sharp & Dohme
- Novartis
- Novo Nordisk
- Pfizer
- Ranbaxy
- Rexim SA (Degussa)
- Roche
- Sanofi-Aventis
- Schering-Plough
- Takeda
- Mitsubishi Tanabe Pharma
- Watson
- Wyeth
- Exports
- Research & Development
- SFDA initiatives
- Zhangjiang Hi-Tech Park
- Beijing Union Pharmaceutical Factory
- Bayer
- Pharmaceutical Regulatory Analysis
- Pharmaceutical Registration
- Revised Provisions for Drug Registration
- State Food and Drug Administration (SFDA)
- Department of Drug Registration
- Department of Drug Safety & Inspection
- Department of Drug Market Compliance
- Drug Classification
- Biotech regulation
- New Regulatory Legislation
- 2001 DAL Amendments
- The Drug Import Regulation
- GMP Regulations
- Pharmaceutical Registration/Drug Approval Process
- Clinical trials
- Quality test
- Certification
- Packaging Regulations
- Post-market Surveillance
- Licences of 160 drug firms revoked in 2006
- China Uncovers 1,001 Commercial Bribery Cases
- Pharmaceutical Advertising
- Patent Protection & Intellectual Property Rights
- Administrative Protection
- Pharmaceutical Pricing and Reimbursement
- Pricing
- Pricing Sector Developments
- Provincial governments
- Reimbursement Lists
- New Rule on Prescription of Drugs Effective May 2007
- Pharmaceutical Distribution
- Distribution System Reform
- Internet Pharmaceutical Distribution
- Pharmaceutical retail
- Shenzen Nepstar
- Distributors
- Chindex
- Hainan Kangtong Pharmaceutical Co Ltd.
- Huazhong Pharmaceutical Co. Ltd.
- Hunan Provincial Medicines & Health Products Import & Export Corp.
- Shandong Medicines & Health Products Import & Export Corp.
- Simcere Pharmaceutical Group
- Sincer Pharmchem Ltd
- Sinochem Jiangsu Suzhou Import Export Corp.
- Tianjin Medicines & Health Products Import & Export Corp.
- Healthcare Analysis
- Demographics
- Population
- Birth Rate
- Death Rate
- Infant Mortality
- Life Expectancy at Birth
- Public Health
- Causes of Death
- Incidence of Communicable Diseases
- Incidence of Non-communicable Diseases
- HIV/AIDS
- Healthcare System
- US$124 Billion Healthcare Reform Plan
- Ministry of Health
- Hospitals
- Rural Healthcare
- Health Insurance
- Background
- Medical Insurance to Cover all Urban Citizens by 2010
- New Co-operative Medical Scheme (formerly Rural Co-operative Medical
Scheme)
- Commercial Medical Insurance
- Red Cross Society of China
- Health Expenditure
- Healthcare Infrastructure
- Healthcare Personnel
- DIRECTORY
- Government Organisations
- Methodology & Sources
List of Tables
- Summary of Key Data Projections, 2009-2014
- Summary of the Chinese Pharmaceutical Market, 2009
- Market Projections, 2009-2014
- SWOT Analysis of the Chinese Pharmaceutical Market, 2009
- Espicom Analysis of China' s Health Sector
- Imports of Pharmaceuticals by Category, 2003-2007 (US$000s)
- Import Trends
- Leading Suppliers of Raw Materials, 2007 (US$000s)
- Leading Suppliers of Medicaments, 2007 (US$000s)
- TCM Industrial Output Value (Billion Yuan) 2000-2007
- Dragon Pharmaceuticals Revenues by Segment, 2007 (US$ millions)
- Exports of Pharmaceuticals, 2003-07 (US$000s)
- Export Trends
- Leading Destinations, 2007 (US$000s)
- Nepstar Drugstores by City
- Summary of Demographic Data, 2006-07
- Projected Population, 2009-2014
- NCMS Funding and Expenditure 2005
- Healthcare Expenditure, 2006
- Projected Health Expenditure, 2009-2014
- Hospitals & Beds, 2007
- Hospital Bed Projections, 2009-2014
- Admissions, 2002-2007 (millions)
- Hospital Admissions by Type 2005, (10,000s)
- Hospital Bed Utilisation Statistics, 1997-2007
- Projected Number of Physicians, 2009-2014 (000s)
INDIA
- EXECUTIVE SUMMARY
- Introduction
- Pharmaceutical Market Analysis
- Size
- Market Structure
- Projections & Outlook
- Imports
- Raw Material Imports
- Finished Medicament Imports
- Domestic Manufacturing
- Domestic Production
- BCG Vaccine Laboratory, Chennai
- Trade Association(s)
- Local Manufacturers
- Alembic Ltd
- Aurobindo Pharma
- Biocon
- Blue Cross Laboratories Ltd
- Cipla Ltd
- Claris Lifesciences
- Dr. Reddy' s Laboratories Ltd
- Glenmark Pharmaceuticals
- Jubilant Organosys
- Lupin Limited
- Matrix Laboratories
- Natco Pharma
- Orchid Chemicals & Pharmaceuticals Ltd
- Piramal Healthcare
- Ranbaxy Laboratories Ltd
- Strides Arcolab
- Sun Pharma
- Torrent Pharmaceuticals
- Wockhardt Ltd
- Zydus Cadila
- Multinational Manufacturers
- Actavis
- GlaxoSmithKline
- Pfizer India
- sanofi-aventis
- Exports
- Research & Development
- Traditional Indian Medicines
- Pharmaceutical Regulatory Analysis
- Pharmaceutical Regulation
- National Pharmaceuticals Policy 2006
- Pharmaceutical Registration
- DGCI set to co-ordinate drug approvals
- Advertising
- Pricing
- Drugs (Prices Control) Amendment Order and Second Amendment Order, 2006
- Drug Price Control Review Committee
- Intellectual Property
- Background to Pharmaceutical Patents
- Mashelkar Committee Report, December 2006
- The Patents (Amendments) Bill, 2005
- Compulsory Licensing
- Pre- & Post-Grant Opposition
- Mailbox Applications
- Other Issues
- The Patents (Amendment) Rules 2006
- Previous Patents Act Amendments and Exclusive Marketing Rights
- Glivec/Gleevec Patent Setback for Novartis
- Pharmaceutical Distribution
- Medical Stores Organisation
- Healthcare Analysis
- Demographics
- Population
- Birth Rate
- Death Rate
- Infant Mortality
- Life Expectancy at Birth
- Public Health
- Causes of Death
- Communicable and Non-communicable Diseases
- National Rural Health Mission
- Child Survival and Safe Motherhood
- National Health Programmes for Disease Control/Eradication
- National Vector Borne Disease Control Programme
- Malaria
- Filariasis
- Kala-azar
- Japanese Encephalitis
- National Programme for the Control of Blindness
- National Leprosy Eradication Programme
- National Tuberculosis Control Programme
- HIV/AIDS
- National AIDS Control Programme
- National Programme for Prevention and Control of Diabetes,
Cardiovascular Disease and Stroke
- Cancer
- Healthcare System
- Department of Health and Family Welfare
- The Department of AYUSH
- Health Insurance
- Apollo Family Health Plan
- Health Expenditure
- Healthcare Infrastructure
- All India Institute of Medical Sciences (AIIMS)
- Safdarjung Hospital, New Delhi
- Dr. Ram Manohar Lohia Hospital, New Delhi
- JIPMER Hospital, Pondicherry
- PGIMER Nehru Hospital, Chandigarh
- Lady Hardinge Medical College Associated Hospitals, New Delhi
- Tata Memorial Centre
- Private Hospitals and Clinics
- Apollo Hospitals Group
- Fortis Healthcare
- Max Healthcare
- Other Commercial Providers
- Primary Care
- First Aid and Disaster Relief
- St. John Ambulance
- Indian Red Cross Society
- Healthcare for the Underprivileged, Scheduled Castes and Scheduled Tribes
- Medical Care for Remote & Marginalised Tribal & Nomadic Communities
- Healthcare Personnel
- DIRECTORY
- Government Organisations
- Trade Associations
- Methodology & Sources
List of Tables
- Summary Key Data Projections, 2009-2014
- Summary of the Indian Pharmaceutical Market, 2009
- Market Projections, 2009-2014
- SWOT Analysis of the Indian Pharmaceutical Market
- Espicom Analysis of the Indian Pharmaceutical Market, 2009
- Pharmaceutical Import Summary, 2003-2007 (US$000s)
- Leading Suppliers, 2007 (US$000s)
- Leading Suppliers of Raw Materials, 2007
- Leading Suppliers of Finished Medicaments, 2007
- Imports of Pharmaceuticals, 2003-2007 (US$000s)
- Pharmaceutical Import Trends
- Leading Suppliers, 2007 (US$000s)
- Leading Suppliers by Category, 2007 (US$000s)
- Alembic: Manufacturing Facilities
- Alembic: FDA ANDA Approvals, 2009
- Alembic: Financial Results 2005-2009
- Aurobindo Pharma: Manufacturing Facilities
- Aurobindo Pharma: ANDA Approvals, 2007-2009
- Cephazone Pharma: FDA ANDA Approval, 2007
- Aurobindo Pharma: Financial Results, 2005-2009
- Biocon: Financial Results, 2005-2009
- Cipla: Manufacturing Facilities
- Cipla: FDA ANDA Approvals, 2007-2009
- Cipla: Tentative FDA ANDA Approvals
- Cipla: Tentative FDA NDA Approvals
- Cipla: Financial Results, 2005-2009
- Claris Lifesciences: FDA ANDA Approvals, 2008
- Dr. Reddy' s: Manufacturing Facilities
- Dr. Reddy' s: FDA ANDA Approvals, 2007-2009
- Dr. Reddy' s: Financial Summary, 2005-2009
- Glenmark: Manufacturing Facilities
- Glenmark: FDA ANDA Approvals, 2007-2009
- Glenmark: Financial Results, 2005-2009
- Jubilant Organosys: FDA ANDA Approvals, 2004-2009
- Jubilant Organosys: Financial Results, 2005-2009
- Lupin: Manufacturing Facilities
- Lupin: FDA ANDA Approvals 2007-2009
- Lupin: Tentative FDA Approvals
- Lupin: Financial Results, 2005-2009
- Matrix: Manufacturing Facilities
- Matrix: FDA ANDA Approvals, 2008-2009
- Matrix: Tentative ANDA Approvals
- Matrix: Financial Results, 2004-2008
- Natco Pharma Financial Results, 2003-2007
- Orchid: Manufacturing Facilities
- Orchid' s Top-10 Brands
- Orchid: FDA ANDA Approvals, 2007-2009
- Orchid: Financial Results, 2005-2009
- Piramal Healthcare: Manufacturing Facilities
- Piramal Healthcare: Financial Results, 2005-2009
- Ranbaxy: Manufacturing Facilities
- Ranbaxy Laboratories: FDA ANDA Approvals, 2007-2009
- Ohm Laboratories: FDA ANDA Approvals, 2006-2008
- Ranbaxy: Financial Results, 2004-2008
- Akorn Strides: FDA ANDA Approvals, 2007-2009
- Sagent Strides: FDA ANDA Approvals
- Strides: Financial Results, 2005-2008
- Sun Pharma: Manufacturing Facilities
- Sun Pharma: FDA ANDA Approvals, 2007-2009
- Caraco Pharmaceutical: ANDA Approvals, 2007-2008
- Sun Pharma: Financial Results, 2005-2009
- Torrent Pharma: FDA ANDA Approvals, 2007-2009
- Torrent Pharma: Financial Results, 2004-2008
- Wockhardt Manufacturing Facilities
- Wockhardt: FDA ANDA Approvals, 2007-2009
- Wockhardt: Financial Results, 2004-2008
- Zydus Cadila: Manufacturing Facilities
- Zydus: ANDA Approvals, 2007-2009
- Zydus Cadila: Financial Results, 2004-2008
- Pharmaceutical Export Summary, 2003-2007 (US$000s)
- Exports of Pharmaceuticals, 2003-2007 (US$000s)
- Pharmaceutical Export Trends
- Pharmaceutical Exports by Destination, 2007 (US$000s)
- Balance of Trade in Pharmaceuticals, 2003-2007 (US$000s)
- Summary of Demographic Data
- Projected Population, 2009-2014
- Reported Incidence of Vaccine Preventable Diseases, 2006
- Reported Malaria Incidence & Deaths, 2006
- Reported Kala-azar Cases & Deaths, 2006
- Suspected Japanese Encephalitis Cases & Deaths, 2006
- Healthcare Expenditure, 2008
- Projected Health Expenditure, 2009-2014
- Hospitals & Beds, 2002
- Hospital Bed Projections, 2009-2014
- Beds in Selected Hospitals, 2007
- AIIMS Hospital Activity, 2005/06
- Projected Number of Physicians, 2009-2014
List of Charts
- Pharmaceutical Imports, Exports & Balance of Trade, 1998-2007 (US$000s)
- Pharmaceutical Imports by Type, 2007 (%)
- Percentage Change in Imports by Type, 2003-2007
- Leading Pharmaceutical Suppliers, 2007 (%)
- Percentage Change in Exports by Type, 2003-2007
- Pharmaceutical Exports by Destination, 2007 (%)
- Population by Age Group, 2006 (%)
- Medically Certified Deaths by Cause, 2000
- Health Expenditure by Source, 2001/02 (%)
RUSSIA
- EXECUTIVE SUMMARY
- Introduction
- Pharmaceutical Market Analysis
- Size
- Market Structure
- Pharmacy Market
- Hospital Market
- Generics Sector
- OTC Sector
- Projections & Outlook
- Imports
- Domestic Manufacturing
- Domestic Production
- Government Programme for the Development of the Pharmaceutical Industry
- Trade Associations
- Local Manufacturers
- Akrikhin
- Bryntsalov A
- JSC Farmacon
- KRKA
- Makiz
- Nizhpharm
- Otechestvennye Lekarstva (Erka Farm)
- Pharmstandard
- Veropharm
- Yugrafarm
- Multinational Manufacturers
- Exports
- Research & Development
- Pharmaceutical Regulatory Analysis
- Pharmaceutical Regulation
- Pharmaceutical Registration
- Clinical Trials
- Import Regulations
- Advertising
- Intellectual Property
- Pharmaceutical Distribution
- Wholesaling
- Protek
- Shreya Corporation
- SIA International
- Retailing
- Healthcare Analysis
- Demographics
- Population
- Birth Rate
- Death Rate
- Infant Mortality
- Life Expectancy at Birth
- Public Health
- Causes of Death
- Incidence of Communicable Disease
- Incidence of Non-Communicable Disease
- HIV/AIDS
- Healthcare System
- Concept for the Development of the Healthcare Sector until 2020
- National ‘Health' Project
- World Bank Projects
- Health Expenditure
- Healthcare Infrastructure
- Healthcare Personnel
- DIRECTORY
- Government Organisations
- Regional Health Authorities
- Trade Associations
- Methodology & Sources
List of Tables
- Summary of Key Data Projections, 2009-2014
- Summary of the Russian Pharmaceutical Market, 2009
- Top Ten ATC Groups by Pharmacy Sales Value, 2006-2008 (%)
- Top Ten ATC Groups by Hospital Purchases, 2006-2008 (%)
- Top Ten Manufacturers by DLO Value, 2007-2008 (%)
- Top Ten ATC Groups by DLO Value, 2007-2008 (%)
- Top Ten Trade Names by DLO Value, 2007-2008 (%)
- Top Ten Generic Drugs in the Retail Sector, Q1-Q2 2007
- Top Ten Generic Companies, Q1-Q2 2007
- Top Ten Manufacturers, Trade Names and ATG Groups in the OTC Market, 2008
- Market Projections, 2009-2014
- SWOT Analysis of the Russian Pharmaceutical Market, 2008
- Espicom Analysis of the Russian Health Sector, 2009
- Imports of Pharmaceuticals by Category, 2003-2007 (US$000s)
- Import Trends, 2006-2007 (US$000s)
- Leading Suppliers of Raw Materials, 2007 (US$000s)
- Leading Suppliers of Medicaments, 2007 (US$000s)
- Leading Suppliers of Medicaments, 2007 (US$000s)
- Top Ten Domestic Producers, 2007 (US$ millions)
- Nizhpharm Sales, 1999-2003
- Pharmstandard Production by Facility, 2008
- Pharmstandard Production by Facility, 2008
- Pharmstandard Financial Results, 2004-2008 (R Millions)
- Pharmstandard Pharmaceutical Sales, 2007-2008
- Pharmstandard Top 10 OTCs, 2007-2008
- Top Pharmaceutical Companies by Sales, 2004-2006 (%)
- Exports of Pharmaceuticals, 2003-2007 (US$000s)
- Export Trends, 2006-2007 (US$000s)
- Leading Destinations, 2007 (US$000s)
- Summary Demographic Data, 2007-2008
- Projected Population, 2009-2014
- Projected Health Expenditure, 2009-2014
- Hospitals and Beds, 2000-2007
- Hospital Bed Projections, 2009-2014
- Inpatient Activity, 2001-2007
- Projected Number of Physicians, 2009-2014
List of Charts
- Radar Graph of the Russian Healthcare System
|
 |
